{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["First line advanced Colorectal patients eligible for treatment with 5-FU, oxaliplatin, and bevacizumab.","Colorectal cancer stage IV"],"disease":["Colorectal Cancer Stage Iv","First Line Advanced Colorectal Patients Eligible For Treatment With 5-fu, Oxaliplatin, And Bevacizumab."],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2537477"],"location":["Greece","Canada","Austria","Sweden","United States","Japan","Australia","France","Germany"],"study_start_month":["11"],"keyword":["Arfolitixorin powder for solution for injection","Calcium folinate"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer.","description":"Primary objectives: Overall response rate (ORR)\nPrimary endpoints: Best ORR, defined as the best response recorded from the start of the study treatment until the end of treatment.","dates":{"creation":"2018-11-15"},"accession":"2537477","cross_references":{"EU Clinical Trials Register":["2017-004154-41"]}}